Skip to main content
. Author manuscript; available in PMC: 2024 Feb 16.
Published in final edited form as: Cell Chem Biol. 2023 Feb 6;30(2):203–213.e17. doi: 10.1016/j.chembiol.2023.01.004

Figure 4. 955 selectively degrades CDK9 and CDK10 by proteomic studies.

Figure 4.

(A-C) Proteome changes induced by 955 or SNS-032 in MOLT4 cells; Blue dot: shared differentially expressed proteins after 0.1 μM 955 or 1 μM SNS032 treatment for 6 h. (D) 955, but not SNS-032, degrades CDK10 in MOLT4 cells. (E) Pre-treatment with MG132 and MLN4924 blocks CDK10 degradation induced by 955. In panels D and E, representative immunoblots are shown and β-actin was used as an equal loading control. The quantification of the relative CDK10 protein content in the immunoblots is presented as mean ± SD (n = 2 biologically independent experiments) in the bar graph (bottom panel). Statistical significance was calculated with unpaired two-tailed Student’s t-tests. *P < 0.05; NS: not significant. See also Figure S5 and Table S3.